Iofina Secures Additional Brine Supply to Boost Iodine Production at IO#11 Plant

Two independent brine supply partners should reduce concentration risk

There is another positive angle here that should not be overlooked. Once this agreement is in place, IO#11 will be served by two independent brine supply partners rather than relying on one source.

That matters because supply diversification can improve reliability. If one source underperforms or faces disruption, the plant is not left leaning entirely on a single partner.

What the extra 45 to 65 metric tonnes of iodine could mean operationally

Iofina expects the new source to increase crystalline iodine production by between 45 and 65 metric tonnes a year at IO#11 once fully operational. Crystalline iodine is the finished iodine product produced from the extraction process.

The company does not provide the current production level at IO#11 in this RNS, so you cannot calculate the exact before-and-after output from disclosed figures alone. Still, a stated increase of around 50% is clearly meaningful at plant level and suggests IO#11 still has room to improve despite only becoming operational in July 2025.

That is a good sign. It suggests the site may have been designed with headroom, and management is now moving to fill it.

Iofina’s pipeline project in Oklahoma is more than just a maintenance update

Sometimes these supply and infrastructure announcements can look a bit dry. This one is more important than it first appears because it combines three useful ingredients: existing capacity, additional feedstock and company-funded execution.

Under the agreement, Iofina will work with its new partner to build a pipeline system that transports brine water to IO#11 and returns the iodine-stripped brine back to the partner’s disposal site. Construction will mostly be managed by the new partner, with preliminary expectations for completion in Q3 2026.

That setup could be attractive for Iofina because it may reduce some operational burden on the company itself, although the detailed responsibilities and commercial terms are not disclosed. Investors should note that project timing is still described as a preliminary expectation, which leaves room for slippage.

How this fits with Iofina’s wider growth story in Oklahoma and the Permian Basin

The timing also matters. Iofina says it is optimising production at IO#11 while also constructing its first plant in the Permian Basin.

That gives the market two parallel growth threads. One is expansion from the existing Oklahoma base, and the other is new capacity from a fresh region. In my view, that is a healthier mix than relying entirely on one major project to do all the heavy lifting.

The company also reminds investors that it operates eight IOsorb plants in Oklahoma and has a ninth under construction in the Permian Basin. So this latest update fits a broader pattern: Iofina is trying to grow production steadily through both new plants and better utilisation of current ones.

What is not disclosed in the Iofina RNS and why that matters

There are still some gaps. The commercial terms of the brine supply agreement are not disclosed, beyond the fact that Iofina is funding the approximately US$1.5 million project.

The RNS also does not disclose the expected revenue, profit contribution or exact payback period from the extra 45 to 65 metric tonnes of annual production. That means investors can see the operational logic, but not yet pin down the financial uplift with precision.

Another missing piece is how quickly the plant gets from construction completion to being fully operational at the higher output level. The company gives a Q3 2026 preliminary construction target, but not a firm date for full production ramp-up.

My view on the Iofina IO#11 brine water agreement

This is a positive update, and I would put it in the category of high-quality operational progress rather than headline-grabbing transformation. The best bit is that it appears to be a relatively modest investment for a meaningful increase in output from an already operational plant.

The second positive is resilience. Having two independent brine supply partners at IO#11 should make the production profile a bit sturdier, which is exactly what you want in a process business.

The main negative is not that anything looks wrong, but that the RNS leaves out some of the financial detail investors would like to see. Without revenue, margin or payback timing data, you are still relying on management’s description of this as a rapid-return project.

Bottom line on Iofina’s additional brine supply agreement for IO#11

Iofina has signed a sensible-looking deal that could increase annual production at IO#11 by approximately 50% for around US$1.5 million, funded by the company. That is the kind of expansion investors generally like – lower cost, based on existing assets, and with a clear operational rationale.

If the pipeline project is completed in Q3 2026 as currently expected and the extra brine delivers the forecast 45 to 65 metric tonnes of iodine a year, this should strengthen the production profile of the Central Oklahoma facility. It will not answer every question about earnings impact, but as far as RNS updates go, this one reads as genuinely constructive.